Episode Details
Back to Episodes
BioVaxys Phase 1 Data Signals Breakthrough in Breast Cancer Therapy | BioVaxys Technology (CSE: BIOV) | The Watchlist E45
Description
In this episode of The Watchlist, listeners hear from Kenneth Kovan, Founder, President, and COO of BioVaxys Technology (CSE: BIOV | OTCQB: BVAXF), as he discusses positive Phase 1 clinical results for the company’s cancer immunotherapy candidate, Maveropepimut-S, in HR-positive, HER2-negative breast cancer. The conversation explores why reductions in Ki-67 levels matter, how MVP-S may enhance hormone therapy, and what’s next as BioVaxys advances toward Phase 2 trials and broader validation of its DPX platform.
This podcast is made in partnership with BioVaxys Technology. For our full disclaimer, visit: https://themarketonline.ca/disclaimer
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.